Unknown

Dataset Information

0

Outcome of pediatric non-Hodgkin lymphoma in Central America: A report of the Association of Pediatric Hematology Oncology of Central America (AHOPCA).


ABSTRACT: BACKGROUND:Treating B-non-Hodgkin lymphoma (B-NHL) in lower-income countries is challenging because of imprecise diagnosis, the increased risk of fatal toxicity associated with advanced disease at presentation, and limited supportive care. PROCEDURE:Central American patients with newly diagnosed stage I or II B-NHL received a modified Berlin-Frankfurt-Münster (BFM) regimen including a prephase (prednisone, cyclophosphamide) followed by A/B/A courses (A: cytarabine, dexamethasone, etoposide, ifosfamide, methotrexate, and intrathecal therapy; B: cyclophosphamide, dexamethasone, doxorubicin, methotrexate, and intrathecal therapy). Those with stage III or IV NHL received additional courses (B/A/B), intensified for stage IV disease by additional vincristine and methotrexate doses. Patients in poor condition received a second prephase treatment before their chemotherapy courses. RESULTS:Between March 2004 and June 2016, of 405 patients with B-NHL, 386 (109 females) were eligible for treatment. Immunohistochemistry was performed in 177 cases (47.4%) and characterized the disease as mature B-cell lymphoma. Stage distribution was as follows: I/II, 31 (8.1%); III, 252 (65.3%); IV, 93 (24.1%); 10 (2.6%) not available. The 3-year overall survival was 70% for the whole group (86% for stages I/II, 75% for stage III, 58% for stage IV). Events included death during induction (34 patients, 8.8%), relapse/progression (46, 11.9%), death in remission (9, 2.3%), second malignancy (1, 0.26%), and death of unknown cause (1, 0.26%). Twenty-three (6%) patients abandoned or refused therapy. CONCLUSIONS:Approximately 70% of children with B-NHL from Central America experienced long-term, disease-free survival with a modified BFM schedule. Toxic death and relapse/resistant disease were the main reasons for treatment failure.

SUBMITTER: Pena-Hernandez A 

PROVIDER: S-EPMC6428601 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Outcome of pediatric non-Hodgkin lymphoma in Central America: A report of the Association of Pediatric Hematology Oncology of Central America (AHOPCA).

Peña-Hernandez Armando A   Ortiz Roberta R   Garrido Claudia C   Gomez-Garcia Wendy W   Fuentes-Alabi Soad S   Martinez Roxana R   Metzger Monika L ML   Chantada Guillermo L GL   Ribeiro Raul C RC  

Pediatric blood & cancer 20190124 5


<h4>Background</h4>Treating B-non-Hodgkin lymphoma (B-NHL) in lower-income countries is challenging because of imprecise diagnosis, the increased risk of fatal toxicity associated with advanced disease at presentation, and limited supportive care.<h4>Procedure</h4>Central American patients with newly diagnosed stage I or II B-NHL received a modified Berlin-Frankfurt-Münster (BFM) regimen including a prephase (prednisone, cyclophosphamide) followed by A/B/A courses (A: cytarabine, dexamethasone,  ...[more]

Similar Datasets

| S-EPMC9030963 | biostudies-literature
| S-EPMC4981978 | biostudies-literature
| S-EPMC6208959 | biostudies-other
| S-EPMC3092025 | biostudies-literature
| S-EPMC7698412 | biostudies-literature
| S-EPMC10267092 | biostudies-literature
| S-EPMC6690044 | biostudies-literature
| S-EPMC5699946 | biostudies-literature
| S-EPMC5561546 | biostudies-literature
| S-EPMC6342230 | biostudies-literature